Fortress Biotech, Inc.

NASDAQ:FBIO

Biotechnology

Healthcare
$1.89 -1.79%

-$0.06 today

Market cap
$63.03M
Beta
1.23
P/E (TTM)
0.7
EPS (TTM)
$4.05
52W Low $1.70High $4.53

Volume 0.41M

Average 0.43M

FBIO Inventory

Raw materials, work in progress, and finished goods held for sale.

Fortress Biotech, Inc.NASDAQ: FBIO

Inventory · Q1 FY2026 · quarter ended Mar 2026

Inventory falls 25.6% from a year ago

Inventory stood at $9.29M at the end of Q1 FY2026, down 25.6% from a year earlier and down 3.4% from the prior quarter. Over 3 fiscal years it compounded at -12.1% a year.

Context

  • Inventory amounted to 2.6% of total assets at the end of Q1 FY2026, down 4.4 pp from a year earlier.
  • Inventory increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether inventory keeps falling in the next quarterly balance sheet after a -25.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$9.29M-3.4% QoQ
Last fiscal yearDec 2025
$9.62M-33.3% YoY
Year agoMar 2025
$12.5M-25.6% since
Inventory past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-25.6%——
1 year-33.3%——
3-year CAGR-12.1%——
5-year CAGR——
10-year CAGR——

Inventory history

USD · from the balance sheet

Latest · FY2025
9.62M USD
Year-over-year change
-33.3%
4-year CAGR
-0.6%

Inventory vs competitors

How FBIO compares with its peers on the latest reported figures

  • FBIO's Mar 2026 inventory of $9.29M is the highest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of -25.6% is the highest of 2, against a peer median of -43.6%.
  • Inventory amounts to 2.6% of total assets for FBIO, versus a peer median of 0.0%.
FBIO Competitors Peer median
Inventory for FBIO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
FBIOFortress Biotech, Inc.Mar 2026$9.29M -25.6%-12.1%2.6%
NTRBNutriband Inc.Apr 2026$121.49K -43.6%-19.9%1.8%
RLMDRelmada Therapeutics, Inc.Mar 2026$0 ——0.0%
IMUXImmunic, Inc.Mar 2026$0 ——0.0%
VXRTVaxart, Inc.Mar 2026$0 ——0.0%
PMVPPMV Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
ADAGAdagene Inc.Dec 2025$0 ——0.0%
XBITXBiotech Inc.Mar 2026$0 ——0.0%
GANXGain Therapeutics, Inc.Mar 2026$0 ——0.0%
TCRXTScan Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding FBIO) $0-43.6%-19.9%0.0%

Competitors are the stored peer set for FBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents305.74M178.27M80.93M57.26M79.38M
Short-term Investments00000
Net Receivables23.79M28.35M15.39M10.4M29.94M
Inventory9.86M14.16M10.21M14.43M9.62M
Other Current Assets09.66M10.5M8.28M5.05M
Total Current Assets346.46M230.43M117.02M90.37M123.84M
Property, Plant & Equipment (Net)34.07M33.01M23.5M17.12M14.82M
Goodwill00000
Intangible Assets12.55M27.2M20.29M31.86M27.61M
Long-term Investments2.22M2.69M2.44M1.55M17.66M
Tax Assets(2.22M)(2.69M)000
Other Non-current Assets3.42M3.66M4.28M3.32M1.62M
Total Non-current Assets50.04M63.87M50.5M53.85M61.71M
Total Assets396.5M294.3M167.53M144.22M185.55M
Account Payables47.43M57.24M34.81M31.64M14.24M
Short-term Debt5.32M10.18M3M625K0
Tax Payables345K722K843K932K356K
Deferred Revenue2.61M728K000
Other Current Liabilities34.42M46.62M9.06M4.84M2.31M
Total Current Liabilities101.04M127.72M84.91M71.4M49.74M
Long-term Debt46.56M93.14M60.86M57.96M59.5M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities2.03M1.85M1.89M1.76M1.45M
Total Non-current Liabilities69.58M116.56M81.03M74.47M73.62M
Total Liabilities170.63M244.28M165.94M145.87M123.37M
Common Stock101K110K15K28K32K
Retained Earnings(547.46M)(634.23M)(694.87M)(740.87M)(734.05M)
Accumulated OCI00000
Other Stockholders Equity0(103K)000
Minority Interest117.2M8.3M(20.96M)(24.38M)12.31M
Total Equity225.88M50.03M1.59M(1.64M)62.18M
Total Debt74.98M127.34M84.66M75.96M74.3M
Net Debt(230.77M)(50.92M)3.73M18.7M(5.08M)

Fortress Biotech, Inc.

NASDAQ:FBIO

Intrinsic Alpha fair value

Locked

Current Price

$1.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.